New Formulations of Existing Antidepressants

No abstract is available for this paper.

• Publication year

  2004

• Venue

  CNS Drugs

• Publication date

  2004-08-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.2165/00023210-200418080-00003PMID 15182220
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Drug Chirality and its Clinical Significance

  2012cited by this paper
• Venlafaxine

  2012cited by this paper
• Once-Weekly Fluoxetine

  2012cited by this paper
• The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer

  2005cited by this paper
• Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor

  2004cited by this paper
• Paroxetine Controlled Release

  2004cited by this paper
• Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea.

  2003cited by this paper
• Potential new drug delivery systems for antidepressants: an overview.

  2003cited by this paper
• Efficacy of controlled-release paroxetine in the treatment of late-life depression.

  2003cited by this paper
• Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea.

  2003cited by this paper
• Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care.

  2003cited by this paper
• Efficacy Comparison of Escitalopram and Citalopram in the Treatment of Major Depressive Disorder: Pooled Analysis of Placebo-Controlled Trials

  2002cited by this paper
• Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care

  2002cited by this paper
• Intravenous mirtazapine in the treatment of depressed inpatients.

  2002cited by this paper
• Fluoxetine dose and outcome in antidepressant drug trials

  2002cited by this paper
• Treatment approaches to major depressive disorder relapse. Part 1: dose increase.

  2002cited by this paper
• Treatment Approaches to Major Depressive Disorder Relapse

  2002cited by this paper
• Treatment approaches to major depressive disorder relapse. Part 2: reinitiation of antidepressant treatment.

  2002cited by this paper
• Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.

  2002cited by this paper
• Enantiomers' potential in psychopharmacology--a critical analysis with special emphasis on the antidepressant escitalopram.

  2002cited by this paper
• Cohort Experience in 39 Psychiatric Outpatients with High Doses of an Enteric-Coated Weekly Formulation of Fluoxetine

  2002cited by this paper
• Treatment Approaches to Major Depressive Disorder Relapse

  2002cited by this paper
• Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression.

  2002cited by this paper
• Third-Generation Antidepressants

  2001cited by this paper
• Irritable bowel syndrome, anxiety, and depression: what are the links?

  2001cited by this paper
• Do some antidepressants work faster than others?

  2001cited by this paper
• Depresssion--emerging insights from neurobiology.

  2001cited by this paper
• Patient perspectives on once-weekly fluoxetine.

  2001cited by this paper
• Venlafaxine Extended-Release

  2001cited by this paper
• Bioequivalence Trial of Orally Disintegrating Mirtazapine Tablets and Conventional Oral Mirtazapine Tablets in Healthy Volunteers

  2001cited by this paper
• Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model.

  2001cited by this paper
• Patient compliance with enteric-coated weekly fluoxetine during continuation treatment of major depressive disorder.

  2001cited by this paper
• Exploring treatment alternatives: weekly dosing of fluoxetine for the continuation phase of major depressive disorder.

  2001cited by this paper
• Patient compliance with enteric-coated weekly fluoxetine during continuation treatment of major depressive disorder.

  2001cited by this paper
• Clinical Pharmacokinetics of Mirtazapine

  2000cited by this paper
• Chiral switches.

  2000cited by this paper
• Suicide by antidepressant intoxication identified at autopsy in Vienna from 1991-1997: the favourable consequences of the increasing use of SSRIs.

  2000cited by this paper
• Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association.

  2000cited by this paper
• Patient compliance to a new enteric-coated weekly formulation of fluoxetine during continuation treatment of major depressive disorder.

  2000cited by this paper
• The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder.

  2000cited by this paper
• Background information and treatment recommendations for patients with HIV/AIDS

  2000cited by this paper
• Classifying depression: should paradigms lost be regained?

  2000cited by this paper
• Cellular mechanisms in the vulnerability to depression and response to antidepressants.

  2000cited by this paper
• Efficacy of intravenous citalopram compared with oral citalopram for severe depression. Safety and efficacy data from a double-blind, double-dummy trial.

  2000cited by this paper
• The antidepressant effects of citalopram are mediated by the S-(+)- and not the R(−)-enantiomer

  1999cited by this paper
• Benefits of citalopram vs viloxazine, both given as an intravenous-to-oral regimen for severe depression

  1998cited by this paper
• Pharmacokinetics and Biotransformation of Mirtazapine in Human Volunteers

  1998cited by this paper
• Citalopram infusion is a useful alternative to tablets in hospitalised patients with depression

  1998cited by this paper
• Cardiovascular effects of fluoxetine in depressed patients with heart disease.

  1998cited by this paper
• Intravenous Treatment of Depressive Patients with an SSRI, Citalopram: Clinical and Pharmacokinetic Aspects

  1997cited by this paper
• The pharmacologic rationale for the clinical use of antidepressants.

  1997cited by this paper
• Mirtazapine: clinical advantages in the treatment of depression.

  1997cited by this paper
• Once-Daily Venlafaxine Extended Release (XR) and Venlafaxine Immediate Release (IR) in Outpatients with Major Depression

  1997cited by this paper
• Bioavailability of once-daily venlafaxine extended release compared with the immediate-release formulation in healthy adult volunteers

  1997cited by this paper
• The pharmacologic rationale for the clinical use of antidepressants.

  1997cited by this paper
• Mirtazapine

  1996cited by this paper
• The Selective α2-Adrenoceptor Antagonist Mirtazapine (Org 3770) Enhances Noradrenergic and 5-HT1A-Mediated Serotonergic Neurotransmission

  1995cited by this paper
• Venlafaxine: A Structurally Unique and Novel Antidepressant

  1995cited by this paper
• Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data

  1995cited by this paper
• Venlafaxine. A review of its pharmacology and therapeutic potential in depression.

  1995cited by this paper
• Stereochemical determinants of the nature and consequences of drug metabolism.

  1995cited by this paper
• Bioavailability of mirtazapine from Remeron® tablets after single and multiple oral dosing

  1995cited by this paper
• The α2‐selective adrenoceptor antagonist org 3770 (mirtazapine, Remeron®) enhances noradrenergic and serotonergic transmission

  1995cited by this paper
• Pharmacokinetic Optimisation of Therapy with Newer Antidepressants

  1994cited by this paper
• Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs)

  1994cited by this paper
• Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features.

  1994cited by this paper
• Fast-Acting Antidepressants

  1994cited by this paper
• Introduction of a Composite Parameter to the Pharmacokinetics of Venlafaxine and its Active O‐Desmethyl Metabolite

  1992cited by this paper
• Biochemical, neurophysiological, and behavioral effects of Wy‐45,233 and other identified metabolites of the antidepressant venlafaxine

  1991cited by this paper
• Plasma‐Level Response Relationships with Fluoxetine and Zimelidine

  1990cited by this paper
• Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolites

  1989cited by this paper
• A review of the metabolism and pharmacokinetics of paroxetine in man

  1989cited by this paper
• Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative.

  1986cited by this paper
• Double-blind trial with oral versus intravenous clomipramine in primary depression.

  1983cited by this paper
• Oral and Intravenous Clomipramine (Anafranil) in Depression: A Review of the Work of Dr. G. H. Collins

  1973cited by this paper

• Directly Observed Weekly Fluoxetine for Major Depressive Disorder Among Hemodialysis Patients: A Single-Arm Feasibility Trial

  2022cites this paper
• Higher dose weekly fluoxetine in hemodialysis patients: A case series report

  2020cites this paper
• Thermoresponsive gating membranes embedded with liquid crystal(s) for pulsatile transdermal drug delivery: An overview and perspectives.

  2019cites this paper
• Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled study

  2019cites this paper
• Efficacy and safety of generic escitalopram (Lexacure®) in patients with major depressive disorder: a 6-week multicenter, randomized, rater-blinded, escitalopram-comparative, non-inferiority study

  2015cites this paper
• Alternate Routes of Administration of Antidepressant and Antipsychotic Medications

  2015cites this paper
• Cardiovascular drug development: is it dead or just hibernating?

  2015cites this paper
• Escitalopram

  2012cites this paper
• Antidepressive Therapieoptimierung in einem Fall von chronisch-entzündlicher Darmerkrankung bei unipolarer Depression

  2012cites this paper
• Intravenous mirtazapine.

  2011cites this paper
• Alternative formulations, delivery methods, and administration options for psychotropic medications in elderly patients with behavioral and psychological symptoms of dementia.

  2010cites this paper
• Desvenlafaxine: a new antidepressant or just another one?

  2009cites this paper
• Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause.

  2009cites this paper
• Polymeric materials and formulation technologies for modified-release tablet development.

  2009influential citation
• Long-term behavioral changes after cessation of chronic antidepressant treatment in olfactory bulbectomized rats.

  2007cites this paper
• Paroxetine versus placebo and other agents for depressive disorders: a systematic review and meta-analysis.

  2007cites this paper
• A study of the involvement of melanin-concentrating hormone receptor 1 (MCHR1) in murine models of depression.

  2007cites this paper
• Special Considerations in Research

  2007cites this paper
• Extended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder

  2007cites this paper
• Effectiveness and tolerability of paroxetine controlled release (CR) in the treatment of major depressive disorder: an open‐label, prospective, multi‐center trial in Korea

  2007cites this paper
• Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence.

  2007cites this paper
• Adherence to treatment in mood disorders

  2006cites this paper
• Dosage Form Considerations in Preformulation

  2006cites this paper
• Attitudes toward different formulations of psychotropic drugs

  2006cites this paper
• Advances in psychotropic formulations.

  2006cites this paper
• [Effects of venlafaxine extended release formulation on the clinical management of patients].

  2005cites this paper
• A randomized, double-blind, 24‐week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder*

  2005cites this paper
• Antidepressant choices in primary care: which to use first?

  2004cites this paper
• Atención psiquiátrica y psicológica al paciente oncológico en las etapas finales de la vida

  2004cites this paper
• Paroxetine Controlled Release

  2004cites this paper